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Implication for health policy/practice/research/medical education: {#key1}
==================================================================

Chronic renal failure is one of the causes of immune suppression. In these patients some parasitic infections such as blastocystiosis, cryptosporidiosis and toxoplasmosis have been reported to be more prevalent. This review aimed to give an overview about parasitic infections in patients with renal disorders.

Introduction {#s1}
============

By increasing the life expectancy among mankind population, subsequent incidence of some chronic diseases, such as chronic renal insufficiency (CRI) is increasing ([@R1]). CRI itself results some complications, in which renal function disturbs. When the renal function lost, body cannot sustain equilibrium of electrolytes. Consequently uremia may occur ([@R2]), which is the result of excess non-excreted metabolites accumulation, like urea ([@R3]). Natural state of immune-depression can cause by uremia and subsequent increase in the incidence of infections may happen ([@R4],[@R5]). Around 48% of deaths in CRI patients are associated with these infections ([@R2],[@R6]).

Also reduced immune response to various antigens, has been detected in patients with chronic kidney disease (CKD) who undergoing dialysis treatment ([@R7]-[@R15]). Additionally, it has been found that sepsis-related death is between 100 and 300-times more frequent in patients undergoing hemodialysis comparing to the general population ([@R16]).

Intestinal parasitic infections have been considered as one of the major public health problems, predominantly in developing countries. However, because of some immunological conditions such as intentional suppression of immune response and also some immunodeficiencies in developed countries, some of these parasites have become a problematic issue ([@R17]). Chronic renal diseases are also one of the causes of insufficient immune response to the infections ([@R2],[@R18]).

Considering the important role of parasitic infections in creating complications or deaths in patients with renal problems, in this paper parasitic infections in patients with chronic renal disease is reviewed.

Intestinal parasites {#s2}
====================

There are lots of studies indicating higher prevalence of intestinal parasitic infections in patients with renal disorders, which some are reviewed.

From 2006 to 2007 hemodialysis patients of Campo Mourão city, Brazil were examined for *Blastocystis* sp. and other intestinal parasites and also the associated diarrhea. Thirty three (45.1%) out of 86 hemodialysis patients and 36 (25.7%) out of 146 control individuals were found to be infected by the parasites. The prevalence of intestinal parasitic infections in hemodialysis patients has been reported significantly higher than the healthy individuals. It is suggested that parasitological stool examinations, particularly for *Cryptosporidium* spp. and *Blastocystis* sp., are better to be perform in routine medical follow up examinations of hemodialysis patients ([@R19]).

In another study the prevalence of amoebiasis caused by *Entamoeba histolytica/dispar* in chronic hemodialysis patients has been reported to be about 8% ([@R20]). In Turkey a study carried out on patients with an end-stage renal failure and 150 healthy volunteers. Parasites were found in 62 (43.7%) out of 142 dialysis patients and 19 (12.7%) out of 150 healthy controls. The most prevalent cause of parasitic infection in the dialysis patients were *Blastocystis* sp. (23.9%), *Giardia lamblia* (8.5%), *E. histolytica* (2.1%), *Microsporidia* spp. (2.1%), and *Cryptosporidium* spp. (2.1%) ([@R21]). Intestinal parasitic infections were more prevalent in clinically asymptomatic renal transplant recipients than in patients with chronic haemodialysis and healthy individuals ([@R22]).

Study of Gill *et al.,* in 2013, illustrated that 51.6% of hemodialysis patients were infected by intestinal parasites, but the prevalence of the infections in control group was 61.6%. *Cryptosporidium* antigen was observed only in patients with CKD (24.5%), but not in controls ([@R23]). They reported prevalence of 24.5% for cryptosporidiosis, which was considered to be high, even higher than some of the reports from renal transplant recipient patients ([@R24]) and livestock owners ([@R25],[@R26]), which were at risk of infection. Their study indicated that patients with CKD were at risk of infection with *Cryptosporidium* spp. ([@R23]).

The prevalence of *Cryptosporidium* infection in patients with end-stage of chronic renal failure was investigated and compared to the healthy controls. Fifteen out of 174 patients with dialysis was positive for *Cryptosporidium*, while none of the controls had the infection. The reported prevalence was significantly higher in dialysis patients ([@R27]).

In another study prevalence of *Cryptosporidium* infection among renal transplant recipients, patients referred to hemodialysis and the control group reported 34.8%, 25% and 17.4%, respectively ([@R28]). In the study carried out in Hamadan city, Iran, the prevalence of cryptosporidiosis has been reported 0.55% in renal transplanted patients, which is controversial to the previously mentioned studies ([@R24]).

Also a very interesting report indicated that the prevalence of *Cryptosporidium* infection was 80% in patients with cancer, 25% in diabetics and 35% in dialysis patients ([@R29]), which are considerably higher than those in the reports from general population and diarrheic children ([@R25],[@R30]). In other studies 11.5% of renal transplant and 3.88% of hemodialysis patients were positive for *Cryptosporidium* infection. No positive results were found in the control groups ([@R31]).

Considering spore-forming protozoa, including: *Isospora belli*, *Cryptosporidium parvum*, *Microsporidia* and *Cyclospora cayetanensis* in patients with CKD, it has been reported that 33.3% of these patients were infected by these parasites ([@R32]). In another study, fecal samples of 104 chronic hemodialysis patients and 140 healthy controls were investigated for cryptosporidiosis. The prevalence of *Cryptosporidium* infection observed higher (11.5%) in dialysis patients compared to controls (3.6%) ([@R33]).

Tissue parasites {#s3}
================

Anti-*Toxoplasma* IgG has been reported in 27.3% and 3.6% of 205 dialysis patients with renal insufficiency and 360 healthy controls, respectively ([@R34]). In another similar study, statistically significant higher prevalence has been observed for anti-*Toxoplasma* IgG and IgM seropositivity in hemodialysis patients than controls. So it has been recommended that hemodialysis patients should be tested for anti-*Toxoplasma* IgG and IgM using specific serological tests in order to prevent the disseminated infection ([@R35]).

Other report showed that 36.8% of renal failure patients and 10.5% of normal population were seropositive for anti-*Toxoplasma* IgG and IgM. Also 56.7% and 16.7% of patients with regular hemodialysis and 69% and 24.1% of renal transplanted patients were seropositive for anti-*Toxoplasma* IgG and IgM, respectively ([@R36]). Higher rates of anti-*Toxoplasma* IgG and IgM, in renal transplanted and renal failure patients have also been reported ([@R37],[@R38]). In another investigation significant higher sero-prevalence of toxoplasmosis has been reported in patients with chronic renal failure (38.3%) compared to the healthy controls (15%) ([@R39]).

In a study carried-out in Ahvaz city, southwest of Iran, 29.3% and 7.9% of hemodialysis patients and 26% and 4% of controls were seropositive for anti-*Toxoplasma* IgG and IgM, respectively ([@R40]). Also in other work the prevalence of anti-*Toxoplasma gondii* antibodies in 173 hemodialysis patients with CKD and 40 healthy controls were 56.06% and 1.73% for hemodialysis patients and 20% and 0% for healthy controls, respectively ([@R41]). Finally anti-*Leishmania donovani* antibodies among 1500 multiply transfused hemodialysis patients was (37%) and among 1194 volunteer blood donors was (9%) ([@R42]).

Exoparasites {#s4}
============

*Demodex folliculorum* infestation has been detected in 25.53% of CKD patients and 18.42% of healthy controls ([@R43]). Also the *D. folliculorum* infection reported in 19.54% of dialysis patients and in 10.34% of healthy controls ([@R44]). The mean mite count in patients with *infestation* who were in end stage of renal failure was 6.12/cm^2^ while in normal controls it was 0.31/cm^2^ ([@R45]).

Case reports about parasites in patients with renal disorders {#s5}
=============================================================

Case report studies about parasites in patients with renal disorders are summarized in [Table 1](#T1){ref-type="table"}.

###### Parasites reported in hemodialysis patients in case report studies

  --------------------------- ------------
  Parasite reported           References
  Strongyloides stercoralis   (46-48)
  Leishmania spp              (49,50)
  --------------------------- ------------

Conclusion {#s6}
==========

In conclusion, some parasitic diseases are considered as public health problems especially in developing countries ([@R37],[@R38],[@R51],[@R52]). Patients with chronic kidney diseases are susceptible to be infected by some parasites such as *Blastocystis* sp., *Cryptosporidium* spp., and *Toxoplasma gondii*. Parasitic infections in these patients may make their situation much more complicated. Continues parasitological monitoring of patients with chronic renal failure is recommended for the possible control of the infections.
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